Clinical TrialsZelicapavir successfully met the study's primary virology endpoint in the pooled efficacy population, with a peak viral load reduction of 0.7 log on Day 9 compared to placebo.
Financial PerformanceEnanta ended 1Q25 with cash and marketable securities of $216.7M, which should fund operations into fiscal 2028, providing runway to achieve multiple milestones across their virology and immunology efforts.
Pipeline ExpansionEnanta plans to expand their immunology pipeline with a third program, while advancing their novel KIT inhibitor EDP-1421 through IND-enabling activities and selecting a STAT6 development candidate.